Myriad Genetics Inc (MYGN)

Net profit margin

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019
Net income (ttm)	US$ in thousands	-116,000	-155,200	-234,600	-263,300	-274,400	-248,200	-146,200	-112,000	-77,300	-17,600	-8,200	-27,200	-34,800	-114,800	-225,300	-194,100	-199,500	-148,300	-26,200	-15,300
Revenue (ttm)	US$ in thousands	817,300	794,900	766,400	745,400	731,500	696,200	691,900	675,200	820,600	831,200	839,900	846,300	666,200	590,100	564,400	586,600	627,900	750,000	801,700	822,500
Net profit margin		-14.19%	-19.52%	-30.61%	-35.32%	-37.51%	-35.65%	-21.13%	-16.59%	-9.42%	-2.12%	-0.98%	-3.21%	-5.22%	-19.45%	-39.92%	-33.09%	-31.77%	-19.77%	-3.27%	-1.86%

September 30, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $-116,000K ÷ $817,300K
= -14.19%

The net profit margin of Myriad Genetics Inc has shown significant fluctuations over the past several quarters, ranging from -39.92% to -0.98%. The trend indicates inconsistency in the company's ability to convert revenue into profit, with some periods experiencing substantial losses. The most recent net profit margin of -14.19% suggests that the company's profitability remains a concern, as it indicates that for every dollar of revenue generated, Myriad Genetics Inc is currently incurring a net loss of approximately $0.14. The negative net profit margins observed in many periods signal potential operational inefficiencies or challenges in cost management that the company may need to address to improve its overall financial performance.